Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhu, Jing ^a   Wang, Jing ^a   Shi, Zhiao ^b,c   Franklin, Jeffrey L ^b,d   Deane, Natasha G ^b,e   Coffey, Robert J ^b,d   Beauchamp, R Daniel ^b,d   Zhang, Bing ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE FUNCTION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; SOMATIC MUTATION; SURVIVAL RATE; UPREGULATION;

ANIMALS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MALE; MICE; NEOPLASM PROTEINS; NEURAL NETWORKS (COMPUTER); WNT SIGNALING PATHWAY;

EID: 84896691027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079282     Document Type: Article

References (51)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6: 479-507.
3. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113. (Pubitemid 350134889)
4. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799. (Pubitemid 39070849)
5. TCGA Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
6. TCGA Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Molecular systems biology 3: 140.
8. Vandin F, Upfal E, Raphael BJ (2011) Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 18: 507-522.
9. Zhang B, Shi Z, Duncan DT, Prodduturi N, Marnett LJ, et al. (2011) Relating protein adduction to gene expression changes: a systems approach. Mol Biosyst 7: 2118-2127.
10. Shi M, Beauchamp RD, Zhang B (2012) A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. PLoS One 7: e41292.
11. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
12. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
13. TCGA Research Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
15. Segal E, Friedman N, Koller D, Regev A (2004) A module map showing conditional activity of expression modules in cancer. Nat Genet 36: 1090-1098. (Pubitemid 41184471)
16. Park YK, Franklin JL, Settle SH, Levy SE, Chung E, et al. (2005) Gene expression profile analysis of mouse colon embryonic development. Genesis 41: 1-12. (Pubitemid 40269717)
17. Shi Z, Derow CK, Zhang B (2010) Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression. BMC Systems Biology 4: 74.
18. Resnik P (1999) Semantic similarity in a taxonomy: an information-based measure and its application to problems of ambiguity in natural language. J Artif intel Res 11: 95-130.
19. Monti S, Tamayo P, Mesirov J, Golub TR (2003) Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 52: 91-118.
20. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
21. Liu Y, Hayes DN, Nobel A, Marron J (2008) Statistical significance of clustering for high dimension low sample size data. Journal of the American Statistical Association 103: 1281-1293.
22. Rousseeuw PJ (1987) Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. Journal of Computational and Applied Mathematics 20: 53-65.
23. Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567-6572. (Pubitemid 34526173)
24. Kohler S, Bauer S, Horn D, Robinson PN (2008) Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82: 949-958.
25. Zhang B, Kirov S, Snoddy J (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-748. (Pubitemid 44530021)
26. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
27. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, et al. (2010) Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 16: 4864-4875.
28. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, et al. (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16: 3356-3367.
29. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, et al. (2007) Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131.
30. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, et al. (2011) EMT is the dominant program in human colon cancer. BMC Med Genomics 4: 9.
31. Radtke F, Clevers H (2005) Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904-1909. (Pubitemid 40404692)
32. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
33. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
34. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, et al. (2010) Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138: 958-968.
35. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7: e47054.
36. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, et al. (2012) Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104: 1635-1646.
37. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, et al. (2008) Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14: 3408-3415.
38. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, et al. (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature medicine 19: 619-625.
39. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, et al. (2013) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature medicine 19: 614-618.
40. Ashktorab H, Schaffer AA, Daremipouran M, Smoot DT, Lee E, et al. (2010) Distinct genetic alterations in colorectal cancer. PLoS One 5: e8879.
41. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512. (Pubitemid 28425575)
42. Nakamura T, Tsuchiya K, Watanabe M (2007) Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 42: 705-710. (Pubitemid 47456757)
43. Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5 Suppl 1: 11-15. (Pubitemid 30225451)
44. Wanami LS, Chen HY, Peiro S, Garcia de Herreros A, Bachelder RE (2008) Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp Cell Res 314: 2448-2453.
45. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, et al. (2006) Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66: 46-51. (Pubitemid 43166007)
46. Yang Q, Bermingham NA, Finegold MJ, Zoghbi HY (2001) Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 294: 2155-2158. (Pubitemid 33150670)
47. TCGA Research Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
48. Meyerhardt JA, Li L, Sanoff HK, Carpenter Wt, Schrag D (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30: 608-615.
49. De Gramont A, Van Cutsem E, Tabernero J, Moore MJ, Cunningham D, et al. (2011) AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 29 (suppl 4) : abstr 362.
50. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, et al. (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11-16.
51. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)